Intravitreal Faricimab improves visual and anatomic outcomes for Aflibercept-Resistant nAMD
Intravitreal therapies neutralizing vascular endothelial growth factor (VEGF) have considerably reduced the extent of vision loss in patients with neovascular age-related macular degeneration (nAMD). Nevertheless, there exist a number of limitations to anti-VEGF therapy, including the requirement of repetitive injections and inadequate response in a subset of subjects. As a consequence, novel treatments and delivery systems are being developed to target other complementary mediators implicated in angiogenesis. Faricimab (Vabysmo)is a bispecific antibody targeting VEGF-A and Angiopoietin-2 (Ang-2). Intravitreal faricimab (IVF) may be more efficacious to IVA in regards to allowing longer treatment intervals when employing an optical coherence tomography (OCT)-guided management protocol, In this study, the authors evaluated the short-term benefits of switching nAMD subjects from IVA to IVF when treatment-resistance is encountered using an OCT-guided management protocol in a real-world setting.
A retrospective review was conducted on nAMD patients undergoing IVA therapy at a single private practice institution. Subjects were divided into Study and Control groups. Both Study and Control subjects had undergone ≥6 IVA treatments during the previous 12 months, ≥4 IVA treatments during the previous 6 months, had a central macular thickness (CMT) on optical coherence tomography (OCT) of ≥300 microns, and had observable intraretinal and/or subretinal fluid on OCT prior to group assignment. Study subjects were switched from IVA to IVF and received 3 treatments within 4 months. Control subjects remained on IVA during the same time period and received 3 treatments within 4 months.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.